tbuckley/cabot-search huggingface dataset:
A phase 1b study of the cancer stem cell inhibitor BBI608 administered with paclitaxel in patients with advanced malignancies.
Authors: Matthew Hitron, Joe Stephenson, Kim N. Chi, William Jeffery Edenfield, David Leggett, Youzhi Li, Wei Li, Keyur Gada, Chiang Li
Journal: Journal of Clinical Oncology (2014)

2530 Background: BBI608 is an oral first-in-class cancer stemness inhibitor which inhibits the Stat3, β-catenin and Nanog pathways. Preclinically, potent, broad-spectrum anti-tumor and anti-metastatic activity was observed in vitro and in vivo, alone and in combination with other agents. BBI608 with paclitaxel showed marked synergy in vivo. In a phase I study, BBI608 monotherapy was well tolerated with encouraging signs of anti-tumor activity and a RP2D of 500 mg BID. Methods: A phase Ib dose-escalation study in patients with advanced cancer was undertaken to determine safety, tolerability, RP2D, and preliminary anti-cancer activity of BBI608 plus weekly paclitaxel. BBI608 was administered in 3 escalating dose cohorts (200 mg BID, 400 mg BID, 500 mg BID) in combination with paclitaxel (80 mg/m2 weekly; 3 of every 4 weeks) until progression of disease, unacceptable toxicity, or other discontinuation criteria was met. Results: 24 patients were enrolled. The BBI608 monotherapy RP2D could be given in combination with paclitaxel in full dose. MTD was not determined. No new adverse events were observed, and the safety profile was similar to that of each agent as monotherapy. The most common adverse events included grade 1 and 2 diarrhea, abdominal cramps, nausea, vomiting. Grade 3 events related to protocol therapy occurred in 4 patients and included diarrhea, dehydration, and weakness. No significant pharmacokinetic interactions were observed. Disease control (CR+PR+SD) was observed in 10 of 15 (67%) evaluable patients. Of 5 patients with refractory gastric/GEJ adenocarcinoma enrolled, 2 had PR (48% and 45% regressions), 1 had SD with 25% regression, and 2 (who failed prior taxane) had prolonged SD ≥ 24 wks. Tumor regression or SD ≥ 16 wks was also seen in patients with platinum-resistant ovarian cancer (1 of 2), melanoma (2 of 3), bladder CA (1 of 3) and NSCLC (1 of 1). Conclusions: This phase Ib study demonstrated that BBI608 and weekly paclitaxel can be safely combined at full dose. Encouraging anti-tumor activity was observed across several tumor types, particularly in patients with gastric and GEJ adenocarcinoma. Clinical trial information: NCT01325441.
Some Observations on C57BL Mice with Mammary Adenocarcinoma E0771 Receiving Combination Chemotherapy<xref ref-type="fn" rid="FN1">2</xref>
Authors: Louis Barvick, Louis H. Goodson
Journal: JNCI Journal of the National Cancer Institute (1957)

Some Observations on C57BL Mice with Mammary Adenocarcinoma E0771 Receiving Combination Chemotherapy2 Louis Barvick, Louis Barvick Chemistry Division, Midwest Research Institute, Kansas City, Missouri Search for other works by this author on: Oxford Academic PubMed Google Scholar Louis H. Goodson Louis H. Goodson Chemistry Division, Midwest Research Institute, Kansas City, Missouri Search for other works by this author on: Oxford Academic PubMed Google Scholar 3The authors wish to thank Dr. H. K. B. Allebach for the histologic examination of the slides and Dr. Raymond G. Stone, Jean Seay, and Martha Ibach for their technical assistance. Author Notes JNCI: Journal of the National Cancer Institute, Volume 19, Issue 5, November 1957, Pages 855–865, https://doi.org/10.1093/jnci/19.5.855 Published: 01 November 1957 Article history Received: 10 January 1957 Published: 01 November 1957
HG-73SAFETY AND FEASIBILITY OF A MULTI-INSTITUTIONAL PHASE II TRIAL INCOPORATING BIOPSY AND MOLECULARLY DETERMINED TREATMENT OF CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPG)
Authors: Karen D. Wright, Pratiti Bandopadhayay, Liliana Gourmnerova, Susan N. Chi, Peter Manley, Karen Marcus, Geoffrey Kannan, Anu Banerjee, Oren Becher, Anne Bendel, Daniel Bowers, Amy-Lee Bredlau, Kenneth Cohen, Melani Comito, Jennifer D. Elster, Michael Etzl, Paul G. Fisher, Sharon Gardner, Stewart Goldman, Sridharan Gururangan, Michael H. Handler, Nada Jabado, Matthias Karajannis, Ziad Khatib, Sarah E. Leary, Tobey J. MacDonald, Michelle Monje, Kellie Nazemi, Nathan J. Robison, Joshua Rubin, Eric S. Sandler, Matija Snuderl, Zhihong Joanne Wang, Claire E. Sinai, Lianne Greenspan, Kristen Lawler, Donna Neuberg, Mariella Filbin, Rosalind Segal, Mario L. Suva, Rameen Beroukhim, Keith Ligon, Nalin Gupta, Michael Prados, Mark W. Kieran
Journal: Neuro-Oncology (2016)
Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non–Small-Cell Lung Cancer
Authors: Adrian G. Sacher, Leena Gandhi
Journal: JAMA Oncology (2016)

<h3>Importance</h3> The development of programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) checkpoint inhibitors has changed the landscape of non–small-cell lung cancer (NSCLC) therapy, with 2 approvals from the US Food and Drug Administration of PD-1 inhibitors for second-line therapy. However, the rational use of these agents has been limited by the lack of a definitive predictive biomarker. <h3>Observations</h3> Tumor PD-L1 expression is associated with an increased likelihood of NSCLC response to these agents, although responses can still occur at a low rate in PD-L1–negative tumors. The use of PD-L1 as a predictive biomarker for use of PD-1/PD-L1 inhibitors is limited by the multitude of PD-L1 antibodies, assays, scoring systems, and thresholds for positivity currently used. Alternative biomarkers such as tumor neoantigens identified through whole-exome sequencing and clinical parameters (eg, smoking or oncogene driver status) may also have predictive value. Biomarkers that can direct the rational use of PD-1/PD-L1 checkpoint inhibitors are crucial given the risk of life-threatening immune-related complications associated with these therapies and the reality that most patients still do not benefit from their use. <h3>Conclusions and Relevance</h3> The refinement of existing biomarkers and identification of novel predictive biomarkers will be key to ensuring the effective and safe use of these agents. Since most patients still do not benefit from these agents, it is critical to continue to work to define the select patient population who will derive durable benefit from PD-1/PD-L1 inhibition and identify markers that could have predictive value for combination therapies that could expand the population who benefit.
Involuntary Smoking and Lung Cancer—Some Object Lessons
Authors: Nathan Mantel
Journal: JNCI Journal of the National Cancer Institute (1986)

Journal Article Involuntary Smoking and Lung Cancer—Some Object Lessons Get access Nathan Mantel Nathan Mantel Mathematics, Statistics and Computer Science, The American University, 4900 Auburn Avenue, Bethesda, Maryland 20814 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 76, Issue 6, June 1986, Pages 1261–1263, https://doi.org/10.1093/jnci/76.6.1261-a Published: 01 June 1986
Dietary fat reduction among women with early breast cancer.
Authors: W C Willett
Journal: Journal of Clinical Oncology (1993)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1993.11.11.2061 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8229119 Dietary fat reduction among women with early breast cancer. W C WillettxW C WillettSearch for articles by this author https://doi.org/10.1200/JCO.1993.11.11.2061 PDF "Dietary fat reduction among women with early breast cancer.." Journal of Clinical Oncology, 11(11), pp. 2061–2062© 1993 by American Society of Clinical Oncology
Towards a standard HIV post exposure prophylaxis for healthcare workers in Europe
Authors: V Puro, S Cicalini, G De Carli, F Soldani, G Ippolito
Journal: Eurosurveillance (2004)

Antiretroviral prophylaxis (PEP) after occupational exposure to HIV in healthcare workers (HCWs) is used across Europe, but not in a consistent manner. A panel of experts, funded by the European Commission, formulated a set of recommendations. When it has been decided that the characteristics of the exposure indicate the initiation of PEP, PEP should be started as soon as possible; initiation is discouraged after 72 hours. PEP should be initiated routinely with any triple combination of antiretrovirals approved for the treatment of HIV-infected patients; a two class regimen is to be preferred. The source patient's treatment history should be sought. Counselling, psychological support, HIV testing and clinical evaluation should be performed at baseline, at 6-8 weeks, and at least 6 months post exposure. Additional clinical and laboratory monitoring at one and two weeks should be considered, as adherence with and tolerance of the regimen can highlight adverse reactions and potential toxicity. Routine HIV resistance tests in the source patient, and direct virus assays in the exposed HCW are not recommended.
The psychiatrist and the pain clinic
Authors: I Pilowsky
Journal: American Journal of Psychiatry (1976)

The author discusses the difficulties inherent in the role of the psychiatrist in a pain clinic as well as some of the recurring problems that he has seen in this setting. He states that the psychiatrist brings to the understanding of pain a multidimensional approach, which is hard for nonpsychiatrist clinicians to accept, and valuable psychophysical methods for evaluating and quantifying pain. He discusses aspects of the interplay between intrapsychic and interpersonal factors in the pain experience, particularly the relationship between pain and guilt, and illustrates these aspects with case reports.
Amebic colitis: colonoscopic appearance
Authors: Na Li, Hai-hong Wang, Xiao-jun Zhao, Jian-qiu Sheng
Journal: Endoscopy (2015)

A 65-year-old man was admitted to our hospital with a 2-month history of pain in the right abdomen and intermittent watery diarrhea. He had previously been in good health and had not traveled to the tropics in recent years. On examination, mild tenderness was noted on palpation over the right abdomen. The results of his blood tests were as follows: white blood cell count (WBC) 7.7 × 109/L, neutrophils 78.5 %, red blood cell count (RBC) 3.56 × 1012/L, hemoglobin (Hb) 104 g/L, erythrocyte sedimentation rate (ESR) 23 mm/h. A fecal occult blood test was positive.
NS-11LOW-FIELD POLESTAR N20 MOBILE iMR SYSTEM AS AN ADJUNCT FOR PEDIATRIC BRAIN TUMOR RESECTION: FEASIBILITY, USEFULNESS AND SAFETY
Authors: Salinas Sanz Jose Antonio, Brell Doval Marta, Ibañez Dominguez Javier, Guibelalde del Castillo Mercedes, Rocabado Quintana Sergio Alejandro, Roldan Busto Jordi, Hernandez Bernal Maria Isabel, Ferres Ramis Laia
Journal: Neuro-Oncology (2016)
The DST in children and adolescents with major depressive disorder
Authors: C D Casat, G W Arana, K Powell
Journal: American Journal of Psychiatry (1989)

The authors analyzed dexamethasone suppression test (DST) results from 13 prospective studies on the use of the DST in children and adolescents with psychiatric disorders. Sensitivity of the DST was significantly higher among the children than among the adolescents with major depressive disorder (69.6% and 47.1%, respectively), and specificity was significantly lower (69.7% and 80.2%). Significantly more adolescents with major depressive disorder than with other psychiatric diagnoses, especially conduct disorder, were nonsuppressors. The authors discuss possible explanations for the high DST sensitivity among the children and point out the potential usefulness of the DST in differentiating major depressive disorder from conduct disorder.
Creutzfeldt-Jakob disease and bovine spongiform encephalopathy
Authors: M. Fitzpatrick
Journal: BMJ (1996)

ticipating, or planning to participate, in the study.To produce reliable evidence to guide the future treatment of many millions of women with breast cancer there is an ethical and scientific imperative to continue recruitment into the aTTom study and other studies of the optimum duration of tamoxifen treatment.
Volunteer Physicians for Vietnam
Authors: H L Schiess
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Senate Creates Cystic Fibrosis Caucus
Authors: Rita Rubin
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
RO-17INITIAL EXPERIENCE WITH SPOT SCANNING PROTON THERAPY FOR PEDIATRIC CNS TUMORS AT PROTON THERAPY CENTER IN TRENTO-ITALY
Authors: Barbara Rombi, Sabina Vennarini, Linda Meneghello, Chiara Bonazza, Dino Pedrotti, Annunziata Dipalma, Loris Menegotti, Maurizio Amichetti
Journal: Neuro-Oncology (2016)
NS-15NEUROSURGICAL MANAGEMENT OF TECTAL GLIOMAS
Authors: Andrea Carai, Antonio Marrazzo, Vito Andrea dell'Anna, Alessandro De Benedictis, Raffaella Messina, Franco Randi, Giovanna Stefania Colafati, Antonella Cacchione, Evelina Miele, Angela Mastronuzzi, Carlo Efisio Marras
Journal: Neuro-Oncology (2016)

NS-15. NEUROSURGICAL MANAGEMENT OF TECTAL GLIOMAS Andrea Carai1, Antonio Marrazzo2, Vito Andrea dell’Anna2, Alessandro De Benedictis1, Raffaella Messina1, Franco Randi1, Giovanna Stefania Colafati3, Antonella Cacchione2, Evelina Miele2, Angela Mastronuzzi2, and Carlo Efisio Marras1; Department of Neurosciences and Neurorehabilitation, Neurosurgery Unit, Bambino Gesu Children’s Hospital, Rome, Italy; Department of Hematology and Oncology, Bambino Gesu Children’s Hospital, Rome, Italy; Department of Imaging, Neuroradiology Unit, Rome, Italy Tectal gliomas are a rare entity mostly showing an indolent clinical course. However, in some cases progression of disease prompts medical treatment. We report a series of 12 consecutive patients diagnosed with tectal glioma at the Bambino Gesu Children’s Hospital from 2012 to 2016. Diagnosis was made according to typical radiological features. Mean follow-up was 43 months (4 to 75 months). Symptoms at onset were macrocrania and full fontanelle in congenital cases and headache, vomiting, ataxia, postural instability, short term memory and attention difficulties in older children, suggesting a strong role of hydrocephalus. Mean age at diagnosis was 8 years and girls were three times more frequent than boys. Hydrocephalus was present at the timeof the diagnosis virtually inall cases (10/11). In three caseshydrocephalus was congenital but diagnosis of tectal glioma was made 8 years later in one case, due to limited access to MRI imaging at the time of hydrocephalus treatment. Hydrocephalus was treated by endoscopic ventriculostomy in all patients presenting after 2008. We had a major complication in one girl, suffering acute intracranial hypertension with severe outcome 20 months after diagnosis presumably from unexpected ventriculostomy closure. After that, we propose routine positioning of a Rickham ventricular access device in all children with hydrocephalus secondary to tectal gliomas. Three children showed progression of their tectal lesion or gaze disturbances prompting stereotactic needle biopsy to obtain histological diagnosis and start oncological treatment. Surgical resection was never indicated, as large esophytic lesions were not observed in our series. Neuro-Oncology 18:iii127–iii134, 2016. doi:10.1093/neuonc/now078.15 #The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Parathyroid Hormone-Related Protein-Induced Hypercalcemia in SCID Mice Engrafted With Adult T-Cell Leukemia Cells
Authors: Akifumi Takaori-Kondo, Kazunori Imada, Itsuo Yamamoto, Akane Kunitomi, Yasuharu Numata, Hitoshi Sawada, Takashi Uchiyama
Journal: Blood (1998)
Nutrition in Germany
Authors: G B Mensink, M Thamm, K Haas
Journal: BMJ (1947)

In addition to the German National Health Interview and Examination Survey, the German Nutrition Survey 1998 (GeNuS) was conducted in a subsample of 4030 participants. Among these persons, a comprehensive dietary interview was performed with use of the software DISHES 98. The proportion of 33-34% energy from fat is considerably less than the 40% energy from fat which was estimated about ten years ago. In general, the supply of most vitamins, minerals and trace elements is sufficient. For a part of the population, the intake of dietary fibre, vitamins D and E, folate, zinc, iodine and, among women, also vitamins B1, B2, B6, iron and phosphorus is on a suboptimal level. Observed differences in dietary habits in the eastern and western part of Germany did not have an obviously more favourable dietary pattern in any part of Germany.
LMI-04CHEMOTHERAPY-ONLY STRATEGIES FOR YOUNG CHILDREN NEWLY-DIAGNOSED WITH MALIGNANT BRAIN TUMORS: CAN THEY BE APPLIED SUCCESSFULLY IN DEVELOPING COUNTRIES? THE MALAYSIAN EXPERIENCE
Authors: Jonathan L. Finlay, Wan Ariffin Bin Abdullah, Diana S. Osorio, Lin Hai Peng
Journal: Neuro-Oncology (2016)
The mTOR Kinase Inhibitor AZD-2014 Effectively Reverses XPO1/CRM1 Antagonist KPT-185–induced Glycolysis / Gluconeogenesis, Enhancing Antitumor Effects in Mantle Cell Lymphoma
Authors: Yoko Tabe, Masako Harada, Yuka Miyamae, Hiromichi Matsushita, Kensuke Kojima, Tsutomu Fujimura, Saiko Kazuno, Takashi Ueno, Takashi Miida, Marina Konopleva, Michael Andreeff
Journal: Blood (2014)
Chinese herbal medicine use and risk of end-stage renal disease in patients with chronic kidney disease: is there an immortal time bias?
Authors: Yu-Wen Hu
Journal: Kidney International (2016)

Recently, Lin et al. reported that Chinese herbal medicine use is associated with a significantly reduced risk of end-stage renal disease in patients with chronic kidney disease, with a hazard ratio of 0.41.1Lin M.-Y. Chiu Y.-W. Chang J.-S. et al.Association of prescribed Chinese herbal medicine use with risk of end-stage renal disease in patients with chronic kidney disease.Kidney Int. 2015; 88: 1365-1373Abstract Full Text Full Text PDF PubMed Scopus (56) Google Scholar Furthermore, there seems to be a dose-response relationship—the longer the duration of treatment, the lower the risk of end-stage renal disease. However, “immortal time bias” might explain this result.2Suissa S. Immortal time bias in pharmaco-epidemiology.Am J Epidemiol. 2008; 167: 492-499Crossref PubMed Scopus (1045) Google Scholar, 3Liu J. Weinhandl E.D. Gilbertson D.T. et al.Issues regarding ‘immortal time’ in the analysis of the treatment effects in observational studies.Kidney Int. 2012; 81: 341-350Abstract Full Text Full Text PDF PubMed Scopus (44) Google Scholar “Immortal time” refers to a time interval during which the outcome could not have occurred because of exposure definition. It is also related to the length-biased sampling in the statistical literature.4Wang M.-C. Hazards regression analysis for length-biased data.Biometrika. 1996; 83: 343-354Crossref Scopus (94) Google Scholar In this study, the “user” status is defined during follow-up but not at baseline. Patients who remain without end-stage renal disease longer have a greater chance to receive Chinese herbal medicine and thus are classified as users. For the user group, the time interval between the start of follow-up and the date of the prescription of medicine is the “immortal time.” During this time interval, these patients were actually nonusers, but were erroneously classified as users by study design. Because the “immortal time” exists only in the user group, the bias would always result in a spurious survival benefit from a treatment. Another feature of immortal time bias is that it introduces a false dose-response relationship. For patients with a longer duration of treatment, the “immortal time” is longer, and thus the magnitude of bias becomes larger. Fortunately, appropriate study design or using time-dependent analysis2Suissa S. Immortal time bias in pharmaco-epidemiology.Am J Epidemiol. 2008; 167: 492-499Crossref PubMed Scopus (1045) Google Scholar could address the issue of immortal time bias. We look forward to a reanalysis of the original data. The Authors ReplyKidney InternationalVol. 90Issue 1PreviewYu-Wen Hu raised a question about immortal time effect and how it relates to patients with end-stage renal disease who are prescribed Chinese herbal medicine.1 This concern is common, particularly in observational studies that focus on the effect of treatment. Our reply follows. Full-Text PDF Open Archive
Thoracic radiotherapy and chemotherapy for small-cell lung cancer: the discussion continues.
Authors: J S Tobias, S G Spiro
Journal: Journal of Clinical Oncology (1994)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1994.12.3.643 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8120564 Thoracic radiotherapy and chemotherapy for small-cell lung cancer: the discussion continues. J S TobiasxJ S TobiasSearch for articles by this author , S G SpiroxS G SpiroSearch for articles by this author https://doi.org/10.1200/JCO.1994.12.3.643 PDF "Thoracic radiotherapy and chemotherapy for small-cell lung cancer: the discussion continues.." Journal of Clinical Oncology, 12(3), pp. 643–644© 1994 by American Society of Clinical Oncology